Affordable Access

Access to the full text

Management of ductal pancreatic cancer

Authors
  • Djanani, Angela1
  • Schmiderer, Andreas1
  • Niederreiter, Lukas1
  • Niederreiter, Markus1
  • Tilg, Herbert1
  • 1 Medical University Innsbruck, Department of Internal Medicine I, Gastroenterology, Hepatology, Metabolism & Endocrinology, Anichstr. 35, Innsbruck, 6020, Austria , Innsbruck (Austria)
Type
Published Article
Journal
European Surgery
Publisher
Springer Vienna
Publication Date
May 15, 2019
Volume
51
Issue
3
Pages
135–138
Identifiers
DOI: 10.1007/s10353-019-0583-z
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundThe majority of patients diagnosed with pancreatic cancer have inoperable disease at the time of presentation. For this reason, systemic treatment is the cornerstone of therapy and more options for systemic therapy have now become available than were a decade ago.MethodsIn this short review, we will give an overview on the systemic therapeutic landscape in 2018 and briefly discuss the challenging topic of neoadjuvant therapy.ResultsHowever, there are a lot of unsolved questions and an urgent need of more clinical trials and new therapies.ConclusionsIn conclusion, despite recent advances, there remains much room for improvement in all aspects of treatment for pancreatic cancer.

Report this publication

Statistics

Seen <100 times